JavaScript NENÍ povolen !

Prosím povolte JavaScript.

* Zobrazit nápovědu

Reset

Pracoviště: From Queen Mary University of London Barts and ...

1 záznamů v Medvik Filtry

Článek

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Giovannoni, Gavin
Autor Giovannoni, Gavin From Queen Mary University of London (G.G.), Barts and The London School of Medicine, UK Mellen Center (J.A.C.), Cleveland Clinic, OH Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Düsseldorf, Germany Department of Neurology and Center for Clinical Neuroscience (E.H.), First Medical Faculty, Charles University in Prague, Czech Republic Department of Neurology (K.W.S.), Medical University of Łódź, Poland Sanofi Genzyme (D.H.M., S.L.L., M.A.P.), Cambridge, MA and Evidence Scientific Solutions (S.M.K.), Philadelphia, PA (at the time the work was conducted). g.giovannoni@qmul.ac.uk
Cohen, Jeffrey A
Autor Cohen, Jeffrey A From Queen Mary University of London (G.G.), Barts and The London School of Medicine, UK Mellen Center (J.A.C.), Cleveland Clinic, OH Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Düsseldorf, Germany Department of Neurology and Center for Clinical Neuroscience (E.H.), First Medical Faculty, Charles University in Prague, Czech Republic Department of Neurology (K.W.S.), Medical University of Łódź, Poland Sanofi Genzyme (D.H.M., S.L.L., M.A.P.), Cambridge, MA and Evidence Scientific Solutions (S.M.K.), Philadelphia, PA (at the time the work was conducted)
Coles, Alasdair J
Autor Coles, Alasdair J From Queen Mary University of London (G.G.), Barts and The London School of Medicine, UK Mellen Center (J.A.C.), Cleveland Clinic, OH Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Düsseldorf, Germany Department of Neurology and Center for Clinical Neuroscience (E.H.), First Medical Faculty, Charles University in Prague, Czech Republic Department of Neurology (K.W.S.), Medical University of Łódź, Poland Sanofi Genzyme (D.H.M., S.L.L., M.A.P.), Cambridge, MA and Evidence Scientific Solutions (S.M.K.), Philadelphia, PA (at the time the work was conducted)
Hartung, Hans-Peter
Autor Hartung, Hans-Peter From Queen Mary University of London (G.G.), Barts and The London School of Medicine, UK Mellen Center (J.A.C.), Cleveland Clinic, OH Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Düsseldorf, Germany Department of Neurology and Center for Clinical Neuroscience (E.H.), First Medical Faculty, Charles University in Prague, Czech Republic Department of Neurology (K.W.S.), Medical University of Łódź, Poland Sanofi Genzyme (D.H.M., S.L.L., M.A.P.), Cambridge, MA and Evidence Scientific Solutions (S.M.K.), Philadelphia, PA (at the time the work was conducted)
Havrdova, Eva
Autor Havrdova, Eva From Queen Mary University of London (G.G.), Barts and The London School of Medicine, UK Mellen Center (J.A.C.), Cleveland Clinic, OH Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Düsseldorf, Germany Department of Neurology and Center for Clinical Neuroscience (E.H.), First Medical Faculty, Charles University in Prague, Czech Republic Department of Neurology (K.W.S.), Medical University of Łódź, Poland Sanofi Genzyme (D.H.M., S.L.L., M.A.P.), Cambridge, MA and Evidence Scientific Solutions (S.M.K.), Philadelphia, PA (at the time the work was conducted)
Selmaj, Krzysztof W
Autor Selmaj, Krzysztof W From Queen Mary University of London (G.G.), Barts and The London School of Medicine, UK Mellen Center (J.A.C.), Cleveland Clinic, OH Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Düsseldorf, Germany Department of Neurology and Center for Clinical Neuroscience (E.H.), First Medical Faculty, Charles University in Prague, Czech Republic Department of Neurology (K.W.S.), Medical University of Łódź, Poland Sanofi Genzyme (D.H.M., S.L.L., M.A.P.), Cambridge, MA and Evidence Scientific Solutions (S.M.K.), Philadelphia, PA (at the time the work was conducted)
Margolin, David H
Autor Margolin, David H From Queen Mary University of London (G.G.), Barts and The London School of Medicine, UK Mellen Center (J.A.C.), Cleveland Clinic, OH Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Düsseldorf, Germany Department of Neurology and Center for Clinical Neuroscience (E.H.), First Medical Faculty, Charles University in Prague, Czech Republic Department of Neurology (K.W.S.), Medical University of Łódź, Poland Sanofi Genzyme (D.H.M., S.L.L., M.A.P.), Cambridge, MA and Evidence Scientific Solutions (S.M.K.), Philadelphia, PA (at the time the work was conducted)
Lake, Stephen L
Autor Lake, Stephen L From Queen Mary University of London (G.G.), Barts and The London School of Medicine, UK Mellen Center (J.A.C.), Cleveland Clinic, OH Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Düsseldorf, Germany Department of Neurology and Center for Clinical Neuroscience (E.H.), First Medical Faculty, Charles University in Prague, Czech Republic Department of Neurology (K.W.S.), Medical University of Łódź, Poland Sanofi Genzyme (D.H.M., S.L.L., M.A.P.), Cambridge, MA and Evidence Scientific Solutions (S.M.K.), Philadelphia, PA (at the time the work was conducted)
Kaup, Susan M
Autor Kaup, Susan M From Queen Mary University of London (G.G.), Barts and The London School of Medicine, UK Mellen Center (J.A.C.), Cleveland Clinic, OH Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Düsseldorf, Germany Department of Neurology and Center for Clinical Neuroscience (E.H.), First Medical Faculty, Charles University in Prague, Czech Republic Department of Neurology (K.W.S.), Medical University of Łódź, Poland Sanofi Genzyme (D.H.M., S.L.L., M.A.P.), Cambridge, MA and Evidence Scientific Solutions (S.M.K.), Philadelphia, PA (at the time the work was conducted)
Panzara, Michael A
Autor Panzara, Michael A From Queen Mary University of London (G.G.), Barts and The London School of Medicine, UK Mellen Center (J.A.C.), Cleveland Clinic, OH Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Düsseldorf, Germany Department of Neurology and Center for Clinical Neuroscience (E.H.), First Medical Faculty, Charles University in Prague, Czech Republic Department of Neurology (K.W.S.), Medical University of Łódź, Poland Sanofi Genzyme (D.H.M., S.L.L., M.A.P.), Cambridge, MA and Evidence Scientific Solutions (S.M.K.), Philadelphia, PA (at the time the work was conducted)

Neurology. 2016 ; 87 (19) : 1985-1992. [pub] 20161012

ISSN 1526-632X
Medvik
Zdroj

OBJECTIVE: To characterize effects of alemtuzumab treatment on measures of disability improvement in patients with relapsing-remitting multiple sclerosis (RRMS) with inadequate response (≥1 relapse) to prior therapy. METHODS: Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II, a 2-year randomized, rater-blinded, active-controlled, head-to-head, phase 3 trial, compared efficacy and safety of alemtuzumab 12 mg with subcutaneous interferon-β-1a (SC IFN-β-1a) 44 μg in patients with RRMS. Prespecified and post hoc disability outcomes based on Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC), and Sloan low-contrast letter acuity (SLCLA) are reported, focusing on improvement of preexisting disability in addition to slowing of disability accumulation. RESULTS: Alemtuzumab-treated patients were more likely than SC IFN-β-1a-treated patients to show improvement in EDSS scores (p < 0.0001) on all 7 functional systems. Significantly more alemtuzumab patients demonstrated 6-month confirmed disability improvement. The likelihood of improved vs stable/worsening MSFC scores was greater with alemtuzumab than SC IFN-β-1a (p = 0.0300); improvement in MSFC scores with alemtuzumab was primarily driven by the upper limb coordination and dexterity domain. Alemtuzumab-treated patients had more favorable changes from baseline in SLCLA (2.5% contrast) scores (p = 0.0014) and MSFC + SLCLA composite scores (p = 0.0097) than SC IFN-β-1a-treated patients. CONCLUSIONS: In patients with RRMS and inadequate response to prior disease-modifying therapies, alemtuzumab provides greater benefits than SC IFN-β-1a across several disability outcomes, reflecting improvement of preexisting disabilities. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence (based on rater blinding and a balance in baseline characteristics between arms) that alemtuzumab modifies disability measures favorably compared with SC IFN-β-1a.

Kolekce

Publikováno

Filtry

* Zobrazit nápovědu

* Zobrazit nápovědu

Upřesnit dle MeSH